Tumor response of temozolomide in combination with morphine in a xenograft model of human glioblastoma
Metrics: PDF 1126 views | HTML 2307 views | ?
Anna Lisa Iorio1, Martina da Ros1, Lorenzo Genitori1, Maurizio Lucchesi1, Fabiana Colelli2, Giacomo Signorino2, Francesco Cardile2, Giacomo Laffi3, Maurizio de Martino1, Claudio Pisano2 and Iacopo Sardi1
1Neuro-Oncology Unit, Department of Pediatric Oncology, Meyer Children’s Hospital, Florence, Italy
2BIOGEM Research Institute, Ariano Irpino, Italy
3Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Iacopo Sardi, email: firstname.lastname@example.org
Keywords: temozolomide, glioblastoma, morphine, blood-brain barrier, animal model
Received: November 15, 2016 Accepted: July 13, 2017 Published: August 03, 2017
Despite multimodal treatments comprising, radiation therapy (RT) and chemotherapy with temozolomide (TMZ), the prognosis of glioblastoma multiforme (GBM) remains dismal and consolidated therapy yields a median survival of 14.6 months.
Blood Brain Barrier (BBB) mediated chemoresistance and high dose related toxicity make necessary the development of new therapeutic approach to sensitize GBM to TMZ.
The aim of the present study was to investigate the potential of the treatment morphine plus TMZ metronmic doses (1,77 and 0,9 mg/kg) in GBM therapy.
The effect of morphine, on tumor cell growth and P-glycoprothein (P-gp) activity, was investigate in in vitro models.
The results demonstrated that GBM cells growth is not influenced by morphine treatment and, for the first time, we show that morphine is an inhibitor of the activity of P-gp efflux transporter who is markedly expressed on BBB.
In vivo, response to the treatments TMZ plus morphine was investigated in an orthotopic nude mice model of GBM.
Animals treated with TMZ metronomic doses showed a significant tumor growth inhibition compared to untreated mice and association with morphine appears to improve TMZ efficacy.
Moreover, the combination of morphine with lower dose of TMZ result in a cytostatic effect on tumor growth over the period of the pharmacological treatments.
In conclusion this novel approach could be a successful strategy to overcome chemoresistance and side effects TMZ mediated, reducing drug dosage and improving long term response, in GBM therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.